BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hansson O, Batrla R, Brix B, Carrillo MC, Corradini V, Edelmayer RM, Esquivel RN, Hall C, Lawson J, Bastard NL, Molinuevo JL, Nisenbaum LK, Rutz S, Salamone SJ, Teunissen CE, Traynham C, Umek RM, Vanderstichele H, Vandijck M, Wahl S, Weber CJ, Zetterberg H, Blennow K. The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau. Alzheimers Dement 2021. [PMID: 33788410 DOI: 10.1002/alz.12316] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 15.0] [Reference Citation Analysis]
Number Citing Articles
1 Musso G, Cosma C, Zaninotto M, Gabelli C, Basso D, Plebani M. Pre-analytical variability of the Lumipulse immunoassay for plasma biomarkers of Alzheimer’s disease. Clinical Chemistry and Laboratory Medicine (CCLM) 2022;0. [DOI: 10.1515/cclm-2022-0770] [Reference Citation Analysis]
2 Nojima H, Ito S, Kushida A, Abe A, Motsuchi W, Verbel D, Vandijck M, Jannes G, Vandenbroucke I, Aoyagi K. Clinical utility of cerebrospinal fluid biomarkers measured by LUMIPULSE ® system. Ann Clin Transl Neurol 2022. [DOI: 10.1002/acn3.51681] [Reference Citation Analysis]
3 Blennow K, Stomrud E, Zetterberg H, Borlinghaus N, Corradini V, Manuilova E, Müller-hübner L, Quevenco F, Rutz S, Hansson O. Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer’s disease. Clinical Chemistry and Laboratory Medicine (CCLM) 2022;0. [DOI: 10.1515/cclm-2022-0516] [Reference Citation Analysis]
4 Popp J, Georgescu D, Bürge M, Mundwiler-pachlatko E, Bernasconi L, Felbecker A. Biomarker in der Diagnostik kognitiver Störungen – Empfehlungen der Swiss Memory Clinics. Praxis 2022;111:738-744. [DOI: 10.1024/1661-8157/a003913] [Reference Citation Analysis]
5 Xu C, Zhao L, Dong C. A Review of Application of Aβ42/40 Ratio in Diagnosis and Prognosis of Alzheimer’s Disease. JAD 2022. [DOI: 10.3233/jad-220673] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Hansson O, Edelmayer RM, Boxer AL, Carrillo MC, Mielke MM, Rabinovici GD, Salloway S, Sperling R, Zetterberg H, Teunissen CE. The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease. Alzheimers Dement 2022. [PMID: 35908251 DOI: 10.1002/alz.12756] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
7 Huang S, Wang J, Fan D, Luo T, Li Y, Tu Y, Shen Y, Zeng G, Chen D, Wang Y, Chen L, Wang Y, Guo J. The association of serum uric acid with cognitive impairment and ATN biomarkers. Front Aging Neurosci 2022;14:943380. [DOI: 10.3389/fnagi.2022.943380] [Reference Citation Analysis]
8 Orellana A, García-gonzález P, Valero S, Montrreal L, de Rojas I, Hernández I, Rosende-roca M, Vargas L, Tartari JP, Esteban-de Antonio E, Bojaryn U, Narvaiza L, Alarcón-martín E, Alegret M, Alcolea D, Lleó A, Tárraga L, Pytel V, Cano A, Marquié M, Boada M, Ruiz A. Establishing In-House Cutoffs of CSF Alzheimer’s Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort. IJMS 2022;23:6891. [DOI: 10.3390/ijms23136891] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Studart-neto A, Coutinho AM. From clinical phenotype to proteinopathy: molecular neuroimaging in neurodegenerative dementias. Arq Neuro-Psiquiatr 2022;80:24-35. [DOI: 10.1590/0004-282x-anp-2022-s138] [Reference Citation Analysis]
10 Maschio C, Ni R. Amyloid and Tau Positron Emission Tomography Imaging in Alzheimer’s Disease and Other Tauopathies. Front Aging Neurosci 2022;14:838034. [DOI: 10.3389/fnagi.2022.838034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Lourenço RB, Campos BM, Rizzi L, de Souza MS, Forlenza OV, Talib LL, Joaquim HPG, Cendes F, Balthazar MLF. Functional connectome analysis in Mild Cognitive Impairment: Comparing AD continuum and Suspected Non-Alzheimer Pathology. Brain Connect 2022. [PMID: 35412854 DOI: 10.1089/brain.2021.0154] [Reference Citation Analysis]
12 Soelter TM, Whitlock JH, Williams AS, Hardigan AA, Lasseigne BN. Nucleic acid liquid biopsies in Alzheimer's disease: current state, challenges, and opportunities. Heliyon 2022;8:e09239. [PMID: 35469332 DOI: 10.1016/j.heliyon.2022.e09239] [Reference Citation Analysis]
13 Bouwman FH, Frisoni GB, Johnson SC, Chen X, Engelborghs S, Ikeuchi T, Paquet C, Ritchie C, Bozeat S, Quevenco F, Teunissen C. Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios. Alz & Dem Diag Ass & Dis Mo 2022;14. [DOI: 10.1002/dad2.12314] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Simrén J, Elmgren A, Blennow K, Zetterberg H. Fluid biomarkers in Alzheimer's disease. Advances in Clinical Chemistry 2022. [DOI: 10.1016/bs.acc.2022.09.006] [Reference Citation Analysis]
15 Delaby C, Teunissen CE, Blennow K, Alcolea D, Arisi I, Amar EB, Beaume A, Bedel A, Bellomo G, Bigot‐corbel E, Bjerke M, Blanc‐quintin M, Boada M, Bousiges O, Chapman MD, Demarco ML, D'onofrio M, Dumurgier J, Dufour‐rainfray D, Engelborghs S, Esselmann H, Fogli A, Gabelle A, Galloni E, Gondolf C, Grandhomme F, Grau‐rivera O, Hart M, Ikeuchi T, Jeromin A, Kasuga K, Keshavan A, Khalil M, Körtvelyessy P, Kulczynska‐przybik A, Laplanche J, Lewczuk P, Li Q, Lleó A, Malaplate C, Marquié M, Masters CL, Mroczko B, Nogueira L, Orellana A, Otto M, Oudart J, Paquet C, Paoletti FP, Parnetti L, Perret‐liaudet A, Peoc'h K, Poesen K, Puig‐pijoan A, Quadrio I, Quillard‐muraine M, Rucheton B, Schraen S, Schott JM, Shaw LM, Suárez‐calvet M, Tsolaki M, Tumani H, Udeh‐momoh CT, Vaudran L, Verbeek MM, Verde F, Vermunt L, Vogelgsang J, Wiltfang J, Zetterberg H, Lehmann S. Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's & Dementia. [DOI: 10.1002/alz.12545] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
16 Teunissen CE, Verberk IMW, Thijssen EH, Vermunt L, Hansson O, Zetterberg H, van der Flier WM, Mielke MM, Del Campo M. Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. Lancet Neurol 2022;21:66-77. [PMID: 34838239 DOI: 10.1016/S1474-4422(21)00361-6] [Cited by in Crossref: 64] [Cited by in F6Publishing: 80] [Article Influence: 64.0] [Reference Citation Analysis]
17 Verberk IMW, Misdorp EO, Koelewijn J, Ball AJ, Blennow K, Dage JL, Fandos N, Hansson O, Hirtz C, Janelidze S, Kang S, Kirmess K, Kindermans J, Lee R, Meyer MR, Shan D, Shaw LM, Waligorska T, West T, Zetterberg H, Edelmayer RM, Teunissen CE. Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease-related blood-based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group. Alzheimers Dement 2021. [PMID: 34845818 DOI: 10.1002/alz.12510] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 18.0] [Reference Citation Analysis]
18 Bjorkli C, Louet C, Flo TH, Hemler M, Sandvig A, Sandvig I. In Vivo Microdialysis in Mice Captures Changes in Alzheimer's Disease Cerebrospinal Fluid Biomarkers Consistent with Developing Pathology. J Alzheimers Dis 2021. [PMID: 34719495 DOI: 10.3233/JAD-210715] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Doecke JD, Francois C, Fowler CJ, Stoops E, Bourgeat P, Rainey-Smith SR, Li QX, Masters CL, Martins RN, Villemagne VL, Collins SJ, Vanderstichele HM. Core Alzheimer's disease cerebrospinal fluid biomarker assays are not affected by aspiration or gravity drip extraction methods. Alzheimers Res Ther 2021;13:79. [PMID: 33863377 DOI: 10.1186/s13195-021-00812-9] [Reference Citation Analysis]